Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination
David Baker, Eugenia Forte, Gareth Pryce, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 69, pp. 104425-104425
Open Access | Times Cited: 17

Showing 17 citing articles:

Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review
Patricia K. Coyle, Mark S. Freedman, Bruce A. Cohen, et al.
Annals of Clinical and Translational Neurology (2024) Vol. 11, Iss. 4, pp. 842-855
Open Access | Times Cited: 10
Elucidating the binding specificity of interactive compounds targeting ATP-binding cassette subfamily G member 2 (ABCG2)
Pawan Kumar, Indu Kumari, Rajendra Prasad, et al.
Molecular Diversity (2025)
Open Access
Exploratory analyses of leukocyte responses in hospitalized patients treated with ozanimod following a severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infection
Olivier Courtemanche, Pascale Blais‐Lecours, Sylvie Lesage, et al.
Immunology and Cell Biology (2025)
Open Access
Vaccination in multiple sclerosis: Tackling challenges and paving the way for effective immunization
René Carvajal, Carmen Tur, Blanca Borrás-Bermejo, et al.
Multiple Sclerosis Journal (2025)
Closed Access
SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon Gamma
Georges Katoul Al Rahbani, Christina Woopen, Marie Dunsche, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 684-684
Open Access | Times Cited: 2
Synthesis, radiosynthesis and biochemical evaluation of fluorinated analogues of sphingosine-1-phosphate receptor 3 specific antagonists using PET
Vysakh Puspha Prasad, Stefan Wagner, Petra Keul, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 104, pp. 117697-117697
Open Access | Times Cited: 1
Update des Addendums zu den S3-Leitlinien Morbus Crohn und Colitis ulcerosa: Betreuung von Patienten mit chronisch-entzündlichen Darmerkrankungen in Bezug auf COVID-19 (Version 2.0)
Carsten Schmidt, Andreas Stallmach, Andreas Sturm, et al.
Zeitschrift für Gastroenterologie (2024) Vol. 62, Iss. 04, pp. 517-534
Closed Access | Times Cited: 1
The Current Landscape in the Development of Small-molecule Modulators Targeting Sphingosine-1-phosphate Receptors to Treat Neurodegenerative Diseases
Sidhartha S. Kar, Soumya Ranjan Gharai, Sujit K. Sahu, et al.
Current Topics in Medicinal Chemistry (2024) Vol. 24, Iss. 28, pp. 2431-2446
Closed Access | Times Cited: 1
T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis
Asia‐Sophia Wolf, Anthony Ravussin, Marton König, et al.
JCI Insight (2023) Vol. 8, Iss. 12
Open Access | Times Cited: 4
Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC)
Tjalf Ziemssen, Marie Groth, Veronika Winkelmann, et al.
Vaccines (2023) Vol. 11, Iss. 8, pp. 1374-1374
Open Access | Times Cited: 3
SARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis
Bruce Cree, Rachel Maddux, Amit Bar‐Or, et al.
Annals of Clinical and Translational Neurology (2023) Vol. 10, Iss. 10, pp. 1725-1737
Open Access | Times Cited: 2
Modification of T- and B-cell-associated immuno-pathologic mechanisms in multiple sclerosis by disease modifying therapies: Achievements and opportunities
Joost Smolders, Jörg Hamann, Inge Huitinga
Handbook of clinical neurology (2024), pp. 7-21
Closed Access
Elucidating the binding specificity of interactive compounds targeting ATP binding cassette subfamily G member 2 (ABCG2)
Pawan Ray, Indu Kumari, Rajendra Prasad, et al.
Research Square (Research Square) (2024)
Closed Access
Challenges in Diagnosis of COVID-19 Pneumonia under Ocrelizumab and De-Risking Strategies in Multiple Sclerosis—The Elephant Is (Still) in the Room
Alice Mariottini, A Lotti, Valentina Damato, et al.
Microorganisms (2024) Vol. 12, Iss. 10, pp. 1941-1941
Open Access
Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis
Tina Nie, Yahiya Y. Syed
CNS Drugs (2024) Vol. 38, Iss. 11, pp. 931-941
Closed Access
Advances in Multiple Sclerosis Neurotherapeutics, Neuroprotection, and Risk Mitigation Strategies
Ahmed S. Abdelrahman, Enrique Álvarez
Neurologic Clinics (2023) Vol. 42, Iss. 1, pp. 115-135
Closed Access | Times Cited: 1
Exploring adverse events associated with sphingosine-1-phosphate modulators: a pharmacovigilance study using the FDA Adverse Event Reporting System Database
Ling Wang, Meilin Fang, Weijie Liang, et al.
Research Square (Research Square) (2023)
Open Access
POST-COVID-19 LUNG PATHOGENESIS AND PATHOMORPHOLOGY
S.S. Yashin, Т. А. Федорина, Yuliya Vital'evna Serdobol'skaya, et al.
Ulyanovsk Medico-biological Journal (2023), Iss. 4, pp. 6-20
Open Access

Е Сердобольская, Яшин Сергей, Сергеевич -Старший Преподаватель, et al.
Ulyanovsk Medico-biological Journal (2023), Iss. 4
Open Access
Page 1

Scroll to top